This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Artemis Biomedical | |
|---|---|
| Name | Artemis Biomedical |
| Type | Private |
| Industry | Biotechnology |
| Founded | 2017 |
| Founder | Dr. Eleanor Hart; Marcus Li |
| Headquarters | Boston, Massachusetts, United States |
| Products | Gene therapy vectors; regenerative cell products; diagnostic platforms |
| Num employees | 120 (2025) |
Artemis Biomedical is a privately held biotechnology company based in Boston focused on translation of gene therapies and regenerative medicine into clinical applications. The company concentrates on viral vector engineering, stem cell–derived therapeutics, and point-of-care diagnostics, aiming to bridge academic research and commercial clinical deployment. Artemis Biomedical collaborates with universities, hospitals, and biopharma firms to advance pipelines from preclinical models to human trials.
Artemis Biomedical operates at the intersection of translational science, biomanufacturing, and clinical development, situating itself within the Greater Boston biotech cluster alongside Harvard Medical School, Massachusetts Institute of Technology, Broad Institute, Dana-Farber Cancer Institute, and Massachusetts General Hospital. The company emphasizes platform technologies drawing on advances from labs at Stanford University, University of California, San Francisco, Johns Hopkins University, University of Pennsylvania, and Columbia University. Artemis has built strategic ties to regulatory bodies and industry partners such as the Food and Drug Administration, European Medicines Agency, National Institutes of Health, Wellcome Trust, and private foundations including the Bill & Melinda Gates Foundation.
Founded in 2017 by translational scientist Dr. Eleanor Hart and entrepreneur Marcus Li, Artemis began as a spinout from a collaboration between researchers at Boston Children's Hospital and MIT Koch Institute. Early seed funding included investors from Third Rock Ventures, Flagship Pioneering, ARCH Venture Partners, and angel investors with backgrounds at Genzyme and Amgen. The company relocated to a Cambridge lab complex near Kendall Square and expanded to a GMP facility outside Woburn, Massachusetts after Series B financing with participation from Sequoia Capital and SV Health Investors.
Artemis’ research portfolio blends viral vector design, induced pluripotent stem cell platforms, and diagnostic assays. Core programs draw from methods pioneered at Salk Institute, Rockefeller University, Pasteur Institute, Cold Spring Harbor Laboratory, and Max Planck Society. Product candidates include adeno-associated virus (AAV) capsid variants inspired by engineered vectors described by groups at University of Florida and University of Pennsylvania, mesenchymal stromal cell derivatives leveraging protocols from Mayo Clinic and Cleveland Clinic, and CRISPR-associated editing systems developed in parallel with approaches from University of California, Berkeley and Broad Institute researchers. Artemis also markets a point-of-care molecular diagnostics platform using chemistry and instrument developments comparable to devices from Roche and Abbott Laboratories.
Artemis has initiated multiple early-phase clinical trials in partnership with academic medical centers including Brigham and Women's Hospital, Cincinnati Children's Hospital Medical Center, Vanderbilt University Medical Center, and University College London Hospitals. Trials target rare monogenic diseases, orthopedic regenerative indications, and oncology adjuvant therapies. The company engages with the Food and Drug Administration for Investigational New Drug applications and has submitted dossiers to the European Medicines Agency for parallel development in the European Union. Artemis’ programs have appeared on registries maintained by ClinicalTrials.gov and received grants from the National Heart, Lung, and Blood Institute and National Institute of Neurological Disorders and Stroke.
Artemis maintains research laboratories near Kendall Square and operates a current Good Manufacturing Practice (cGMP) production campus in the Greater Boston area, with contract manufacturing organization partnerships that include Lonza, Thermo Fisher Scientific-affiliated sites, and regional CDMOs tied to Samsung Biologics and Catalent. The firm's bioprocess development draws on technologies from GE Healthcare Life Sciences and single-use bioreactor systems used by peers such as Moderna and BioNTech. Quality systems reference standards promulgated by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and inspection frameworks used by the Food and Drug Administration.
Strategic alliances and translational collaborations involve Harvard University, Yale University, Imperial College London, GlaxoSmithKline, Pfizer, Novartis, and venture funds including New Enterprise Associates and OrbiMed. Public funding and philanthropic awards have come from National Institutes of Health grants, the Wellcome Trust, and disease-focused charities like Cystic Fibrosis Foundation and Alzheimer's Association. Corporate partnerships cover joint development agreements, licensing from academic tech transfer offices such as Boston University Technology Development Office and MIT Technology Licensing Office, and co-investment with corporate venture arms like GV and Roche Venture Fund.
Artemis has attracted scrutiny common to translational biotech, including debates about data transparency related to preclinical efficacy claims and manufacturing yields first reported by investigative coverage in outlets that cited academic scientists from Stanford University, Yale University, and University of Oxford. Critics from patient advocacy groups such as Global Genes and academic ethicists affiliated with Oxford University and Harvard Kennedy School have pressed for clearer patient consent practices and pricing commitments, echoing prior disputes involving companies like Spark Therapeutics and Bluebird Bio. Regulatory inspectors from the Food and Drug Administration and auditors aligned with European Medicines Agency standards have conducted routine inspections, after which Artemis issued corrective action plans and public statements coordinated with partners including Massachusetts Department of Public Health.
Category:Biotechnology companies